Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients

Journal of Clinical Psychiatry

Volumn 68, Issue 8, 2007, Pages 1195-1205

  Stassen, Hans H ^a   Angst, Jules ^a   Hell, Daniel ^a   Scharfetter, Christian ^a   Szegedi, Armin ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; OXAPROTILINE; PAROXETINE; PLACEBO;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INCIDENCE; LATENT PERIOD; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL;

EID: 34548548237     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0805     Document Type: Article

References (38)

1. Montgomery SA, Bech P, Blier P, et al. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J Clin Psychiatry 2002;63:694-699
2. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998;281:1640-1645
3. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996;29:87-96
4. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? a meta-analysis. J Clin Psychiatry 2005;66:148-158
5. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003;60:1228-1235
6. Holsboer F. Antidepressant drug discovery in the postgenomic era. World J Biol Psychiatry 2001;2:165-177
7. Angst J, Stassen HH. Methodische Aspekte von Studien zur antidepressiven Wirksamkeit. In: Steinberg R, Philipp M, Möller HJ, eds. Spezielle Aspekte der Antidepressiven Therapie: Neuere Ergebnisse zu Moclobemid. Munich, Germany: MMV Medizin Verlag München; 1994:147-165
8. Houck PR, Mazumdar S, Koru-Sengul T, et al. Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods. Psychiatry Res 2004;129:209-215
9. Müller DJ, Schulze TG, Macciardi F. et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. Pharmacopsychiatry 2002;35: 157-158
10. Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry 1999;32:56-60
11. Szegedi A, Müller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003;64:413-420
12. Laska EM, Meisner MJ. Nonparametric estimation and testing in a cure model. Biometrics 1992;48:1223-1234
13. Tamura RN, Faries DE, Feng J. Comparing time to onset of response in antidepressant clinical trials using the cure model and the Cramer-von Mises test. Stat Med 2000;19:2169-2184
14. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993;3:127-135
15. Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull 2002;36(suppl 1):suppl 1-17
16. Daniels MJ, Zhao YD. Modelling the random effects covariance matrix in longitudinal data. Stat Med 2003;22:1631-1647
17. Papakostas GI, Perlis RH, Scalia MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006;26: 56-60
18. Statistical analysis software SAS: Proc MIXED versus Proc GLM for random effects analysis. Cary, NC: SAS Institute Inc; 1999
19. Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response. Arch Gen Psychiatry 1987;44:259-264
20. Nemeroff CB, Thase ME, on behalf of the EPIC 014 Study Group. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 2007;41:351-359
21. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001;4:113-118
22. Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001;158:1449-1454
23. Angst J, Stassen HH. Do antidepressants really take several weeks to show effect? In: Leonard BE, ed. Antidepressants. Basel, Switzerland: Birkhauser; 2001:21-30
24. Katz MM, Tekell JL, Bowden CL, et al. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004;29:566-579
25. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60(suppl 22):7-11
26. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003;5(suppl 2):20-35
27. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003;54:227-240
28. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305-315
29. Leon AC, Blier P, Culpepper L, et al. An ideal trial to test differential onset of antidepressant effect. J Clin Psychiatry 2001;62(suppl 4):34-36
30. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
31. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-877
32. Stassen HH, Kuny S, Hell D. The speech analysis approach to determining onset of improvement under antidepressants. Eur Neuropsychopharmacol 1998;8:303-310
33. Kobak KA, Lipsitz JD, Williams JB, et al. A new approach to rater training and certification in a multicenter clinical trial. J Clin Psychopharmacol 2005;25:407-412
34. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-557
35. Burghes AH, Vaessin HE, de La Chapelle A. Genetics: the land between Mendelian and multifactorial inheritance. Science 2001;293:2213-2214
36. Stassen HH, Bridler R, Hell D, et al. Ethnicity-independent genetic basis of functional psychoses: a genotype-to-phenotype approach. Am J Med Genet B Neuropsychiatr Genet 2004;124:101-112
37. Henn FA, Vollmayr B. Neurogenesis and depression: etiology or epiphenomenon? Biol Psychiatry 2004;56:146-150
38. Taylor C, Flicker AD, Devi LA, et al. Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal 2005;17:549-557